

SOTAC PHARMACEUTICALS LIMITED

(Formerly Known as, Sotac Pharmaceuticals Private Limited)



Registered Office :

Plot No.: PF/21, Nr. Acme Pharma,
Opp. Teva Pharma, Sanand GIDC - II,
Sanand, Ahmedabad - 382110. Gujarat (INDIA)

CIN No.: L24230GJ2015PLC085451

Date: August 13, 2024

To,
Listing Compliance Department
National Stock Exchange of India Limited
Exchange Plaza, Bandra Kurla Complex
Bandra East, Mumbai-400051

Dear Sir,

Sub: Outcome of board meeting held on today i.e. on, August 13, 2024, in terms of second proviso to Regulation 30(6) Of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Ref: Sotac Pharmaceuticals Limited (SYMBOL/ISIN: SOTAC/INE002D01012)

In reference to captioned subject, we hereby inform you that the Board of Directors of the Company, in their Board Meeting held on today, i.e. on Tuesday, August 13, 2024, at the Registered Office of the Company situated at Plot No. PF-21, Nr. Acme Pharma, Opp. Teva Pharma Sanand GIDC-II, Sanand Ahmedabad-382110, which was commenced at 02:00pm and concluded at 03:30pm, to have;

1. Considered, approved and taken on record the Unaudited Standalone and Consolidated financial result of the Company for the Quarter ended on June 30, 2024.
2. Approved the Limited Review Report issued by Statutory Auditors of the Company for the Quarter ended on June 30, 2024.
3. Considered and approved all other business as per agenda circulated.

Kindly take the same on your record and oblige us.

Thanking you.

Yours faithfully,

For, Sotac Pharmaceuticals Limited

Sharadkumar Dashrathbhai Patel
Chairman and Managing Director
DIN: 07252252



Place: Ahmedabad

Contact No.: 99135 62852, 87994 83159, 99250 45971



www.sotacpharma.com



sotacpharma@gmail.com

SOTAC PHARMACEUTICALS LIMITED

(Formerly Known as, Sotac Pharmaceuticals Private Limited)



Registered Office :

Plot No.: PF/21, Nr. Acme Pharma,
Opp. Teva Pharma, Sanand GIDC - II,
Sanand, Ahmedabad - 382110. Gujarat (INDIA)
CIN No.: L24230GJ2015PLC085451

Date: August 13, 2024

To,
Listing Compliance Department
National Stock Exchange of India Limited
Exchange Plaza, Bandra Kurla Complex
Bandra East, Mumbai-400051

Dear Sir,

Sub: Submission of Unaudited Standalone and Consolidated Financial Result of the Company for the quarter ended on June 30, 2024 along with Limited Review Report.

Ref: Sotac Pharmaceuticals Limited (SYMBOL/ISIN: SOTAC/INE002D01012)

In reference to captioned subject and pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith the Unaudited Standalone and Consolidated Financial Results of the Company for the Quarter ended on June 30, 2024 along with Limited Review Report issued by Statutory Auditors on the Unaudited Standalone and Consolidated Financial Results for the Quarter ended on June 30, 2024.

Kindly take the same on your record and disseminate the same on your website and oblige us.

Thanking You,

Yours faithfully,

For, Sotac Pharmaceuticals Limited

Sharadkumar Dashrathbhai Patel
Chairman and Managing Director
DIN: 07252252



Place: Ahmedabad

Contact No.: 99135 62852, 87994 83159, 99250 45971



www.sotacpharma.com



sotacpharma@gmail.com



Keyur Shah & Co.
CHARTERED ACCOUNTANTS

CA Keyur Shah

FCA, B.Com, ISA,
FAFP Certified

Limited Review Report on unaudited standalone financial results of Sotac Pharmaceuticals Limited for the Quarter ended 30th June '24 pursuant to Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

To,

The Board of Directors of,

Sotac Pharmaceuticals Limited

We have reviewed the accompanying the statement of unaudited Standalone financial results ("the financial statement") of **Sotac Pharmaceuticals Limited** ("the Company") for the Quarter ended on June 30, '24. The Financial Statement is the responsibility of the Company's Management and has been approved by the Board of Directors, has been prepared in accordance with recognition and measurement principles laid down as per accounting standard prescribed under section 133 of the Companies Act, 2013 and other accounting principles generally accepted in India and in compliance with regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015. Our responsibility is to issue a report on the Statement based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410 "Review of Interim Financial Information performed by the independent Auditor of the Entity", issued by the institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primary to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.



Based on our review conducted as stated above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited Standalone financial results, prepared in accordance with applicable standards and other recognized accounting practices and policies has not disclosed the information require to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For, Keyur Shah & Co.
Chartered Accountants
F.R. No. 141173W




Keyur Shah
Proprietor

M. No. 153774

UDIN: - 24153774BKBOBM4737

Date: - 13th August '24

Place: - Ahmedabad

SOTAC PHARMACEUTICALS LIMITED

(Formerly known as Sotac Pharmaceuticals Private Limited)

Plot No PF-20, Sanand GIDC-II, Nr. ACME Pharam, Opp. Teva Pharam, Sanand GIDC-II, Ahmedabad-382110

Standalone Statement Of Unaudited Financial Result For The Quarter Ended 30th June '24

(INR in Lakhs unless otherwise Specified)

Sr no.	Particulars	Quarter ended on		Year ended on	
		30th June '24	31st March '24	30th June '23	31st March '24
		Unaudited	Audited	Unaudited	Audited
I)	Revenue From Operations	1,301.34	1,631.14	1,891.05	6,710.50
II)	Other Income	43.00	52.82	23.15	131.87
III)	Total Revenue (I+II)	1,344.34	1,683.96	1,914.20	6,842.37
IV)	Expenses				
a)	Cost of Material Consumed	744.81	1,078.09	1,199.35	4,210.80
b)	Purchase of Stock-in-Trade	30.10	89.10	7.73	261.58
c)	Changes in Inventories of Finished Goods/ Work-In-Progress/ Stock in Trade	71.93	(43.90)	66.36	47.61
d)	Employee Benefit Expenses	55.01	61.58	72.27	265.68
e)	Finance Costs	25.69	24.93	34.20	101.34
f)	Depreciation and Amortisation Expense	60.43	73.03	46.27	251.11
g)	Other Expenses	189.06	215.03	319.38	905.36
	Total Expenses (IV)	1,177.03	1,497.86	1,745.56	6,043.48
V)	Profit/(Loss) Before Exceptional & Extraordinary Items & Tax (III-IV)	167.31	186.10	168.64	798.89
VI)	Exceptional/Prior Period Items	-	(0.18)	-	(23.38)
VII)	Profit Before Extraordinary Items & Tax (V-VI)	167.31	185.92	168.64	775.51
VIII)	Extraordinary Items	-	-	-	-
IX)	Profit Before Tax (VII-VIII)	167.31	185.92	168.64	775.51
X)	Tax Expense				
a)	Current Tax	43.55	55.12	45.63	212.64
b)	Deferred Tax	(1.61)	(7.25)	2.48	(8.22)
c)	Income Tax Excess Provisions Related to Earlier Years	-	-	-	(3.79)
	Total Tax Expense (X)	41.94	47.87	48.11	200.63
XI)	Profit / (Loss) For The Period (IX-X)	125.37	138.05	120.53	574.88
XII)	Paidup Equity Share Capital (Face value Rs 10 each)	1,105.00	1,105.00	1,105.00	1,105.00
XIII)	Reserve & Surplus (Excluding Revaluation Reserve)				3,722.44
XIII)	Earnings Per Equity Share-Basic/Diluted (not annualised, for the quarter ended)	1.13	1.25	1.12	5.24

Notes:

[1] The standalone unaudited financial results are prepared in accordance with the Accounting Standards Prescribed under Section 133 of the Companies Act, 2013 read with Rule 7 of the Companies (Accounts) Rules, 2014 (as amended) and other recognised accounting practices and policies, as applicable

[2] The above standalone unaudited financial results for the quarter ended 30th June '24 have been prepared by the Company in accordance with Regulation 33 of SEBI (Listing Obligation & Disclosure Requirements) Regulations 2015 (as amended) and were reviewed and recommended by the Audit Committee of the Board and thereafter were approved and taken on record by the Board of Directors in their meeting held on 13th August '24. A limited review of the above results has been carried out by the statutory auditors of the company.

[3] The figures for the quarter ended 31 March '24 are the Balancing figures between the audited figures in respect of full financial year and the year-to-date figures up to the third quarter ended on 31 december '23 which are subject to limited review.

[4] The figures of the previous period have been re-grouped / rearranged and / or recasted wherever considered necessary.

[5] The Company has Voluntarily adopted the quarterly standalone unaudited financial results for the quarter ended 30th June '24.

[6] Company is mainly engaged in manufacturing of a wide range of pharmaceutical products such as Non Beta-Lactam (general) tablets, Non Beta-Lactam (general) capsules, Non Beta-lactam Syrup and external preparations looking into the nature of business company is operating under single segment hence segment reporting is not applicable to Company.

[7] The Status of investor's complaints during the period ended on 30th June '24 as under:-

Complaints pending at the beginning of the period	0
Complaints received during the period	0
Complaints disposed during the period	0
Complaints resolved at the end of the period	0



For & on behalf of Sotac Pharmaceuticals Limited

Sharad Patel

DIN:07252252

Chairman & Managing Director

Place : Ahmedabad

Date : 13th August, '24



Keyur Shah & Co.
CHARTERED ACCOUNTANTS

CA Keyur Shah

FCA, B.Com, ISA,
FAFP Certified

Auditor's Limited Review Report on unaudited consolidated financial results of Sotac Pharmaceuticals Limited, for the Quarter ended June 30 '24 pursuant to Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

To,

The Board of Directors of,

Sotac Pharmaceuticals Limited

We have reviewed the accompanying Statement of unaudited consolidated Financial Results of **Sotac Pharmaceuticals Limited** ("the Parent") and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group"), for the Quarter ended June 30 '24 ("the Statement"), being submitted by the Parent pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

This Statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Accounting Standard 25 "Interim Financial Reporting" ("AS 25"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures.



A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion. We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

The Statement includes the results of the following entities:

1. Sotac Pharmaceuticals Limited ("Parent")
2. Sotac Healthcare Private Limited ("Subsidiary")
3. Sotac Lifesciences Private Limited ("Subsidiary")
4. Sotac Research Private Limited ("Subsidiary")

Based on our review conducted and procedures performed as stated in above and based on the statement provided by the Management related to parent & subsidiary, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

We did not review the interim financial statements / financial information / financial results of Subsidiary i.e. "Sotac Healthcare Private Limited", "Sotac Research Private Limited" and "Sotac Lifesciences Private Limited" included in the consolidated unaudited financial results, whose interim financial statements / financial information / financial results reflect total revenues of Rs. 1434.64 Lakhs, Nil & Nil, and total net profit/(loss) after tax of Rs. (18.54) Lakhs, 1.80 lakhs & (11.61) Lakhs for the quarter respectively as considered in the consolidated unaudited financial results, whose interim financial statements / financial information/ financial results have not been reviewed by us.



These interim financial statements / financial information / financial results have been provided by the Management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of these subsidiary is based solely on the reports of the Management and the procedures performed by us as stated in above.

Our conclusion on the statement is not modified in respect of the above matters.

For, Keyur Shah & Co.

Chartered Accountants

F.R.No. 141173W



Keyur B.Shah

Proprietor

M No. 153774

UDIN: 24153774BKBOBN1826

Date: - 13th August,'24

Place:- Ahmedabad

SOTAC PHARMACEUTICALS LIMITED

(Formerly known as Sotac Pharmaceuticals Private Limited)

Plot No PF-20, Sanand GIDC-II, Nr. ACME Pharam, Opp. Teva Pharam, Sanand GIDC-II, Ahmedabad-382110

Consolidated Statement Of Unaudited Financial Result For The Quarter Ended 30th June '24

(INR in Lakhs unless otherwise Specified)

Sr no.	Particulars	Quarter ended on		Year ended on	
		30th June '24	31st March '24	30th June '23	31st March '24
		Unaudited	Audited	Unaudited	Audited
I)	Revenue From Operations	2,524.85	2,644.50	2,496.70	10,383.05
II)	Other Income	24.79	35.46	22.99	48.62
III)	Total Revenue (I+II)	2,549.65	2,679.96	2,519.69	10,431.67
IV)	Expenses				
a)	Cost of Material Consumed	1,972.90	2,094.91	1,787.67	7,775.69
b)	Purchase of Stock-in-Trade	30.10	88.43	8.05	261.58
c)	Changes in Inventories of Finished Goods/ Work-In-Progress/ Stock in Trade	(45.47)	(31.04)	(26.16)	(76.10)
d)	Employee Benefit Expenses	95.65	118.53	97.78	399.57
e)	Finance Costs	41.68	34.65	45.82	170.34
f)	Depreciation and Amortisation Expense	74.65	88.22	60.44	310.05
g)	Other Expenses	250.09	256.14	395.77	1,170.77
	Total Expenses (IV)	2,419.60	2,649.84	2,369.37	10,011.90
V)	Profit/(Loss) Before Exceptional & Extraordinary Items & Tax (III-IV)	130.05	30.12	150.32	419.77
VI)	Exceptional/Prior Period Items	-	0.18	-	23.38
VII)	Profit Before Extraordinary Items & Tax (V-VI)	130.05	29.94	150.32	396.39
VIII)	Extraordinary Items	-	-	-	-
IX)	Profit Before Tax (VII-VIII)	130.05	29.94	150.32	396.39
X)	Tax Expense				
a)	Current Tax	7.39	55.12	45.92	212.64
b)	Deferred Tax	(11.98)	(175.91)	6.00	(170.39)
c)	Income Tax Excess Provisions Related to Earlier Years	-	-	-	(3.79)
	Total Tax Expense (X)	(4.60)	(120.79)	51.92	38.46
XI)	Profit / (Loss) For The Period (IX-X)	134.65	150.73	98.40	357.93
XII)	Less: Share of Minorities In subsidiary Companies (loss)/Profit	(10.69)	(13.63)	(9.86)	(70.20)
XIII)	Profit / (Loss) For The Period	145.33	164.36	108.26	428.13
XIV)	Paidup Equity Share Capital (Face value Rs 10 each)	1,105.00	1,105.00	1,105.00	1,105.00
XV)	Reserve & Surplus (Excluding Revaluation Reserve)	-	-	-	3,420.92
XVI)	Earnings Per Equity Share-Basic/Diluted (not annualised, for the quarter ended)	1.32	1.49	1.01	3.90

Dr. P. H.



SOTAC PHARMACEUTICALS LIMITED

(Formerly known as Sotac Pharmaceuticals Private Limited)

Plot No PF-20, Sanand GIDC-II, Nr. ACME Pharam, Opp. Teva Pharam, Sanand GIDC-II, Ahmedabad-382110

Notes:

- [1] The consolidated unaudited financial results are prepared in accordance with the Accounting Standards Prescribed under Section 133 of the Companies Act, 2013 read with Rule 7 of the Companies (Accounts) Rules, 2014 (as amended) and other recognised accounting practices and policies, as applicable.
- [2] The above consolidated unaudited financial results for the quarter ended 30th June '24 have been prepared by the Company in accordance with Regulation 33 of SEBI (Listing Obligation & Disclosure Requirements) Regulations 2015 (as amended) and were reviewed and recommended by the Audit Committee of the Board and thereafter were approved and taken on record by the Board of Directors in their meeting held on 13th August '24. A limited review of the above results has been carried out by the statutory auditors of the company.
- [3] The figures for the quarter ended 31 March, '24 are the Balancing figures between the audited figures in respect of full financial year and the year-to-date figures up to the third quarter ended on 31 december, '23 which are subject to limited review.
- [4] The figures of the previous period have been re-grouped / rearranged and / or recasted wherever considered necessary.
- [5] The Company has Voluntarily adopted the quarterly consolidated unaudited financial results for the quarter ended 30th June '24.
- [6] Company is mainly engaged in manufacturing of of a wide range of pharmaceutical products such as Non Beta-Lactam (general) tablets, Non Beta-Lactam (general) capsules, Non Beta-lactam Syrup and external preparations looking into the nature of business company is operating under single segment hence segment reporting is not applicable to Company.
- [7] The Status of investor's complaints during the year ended on 30th June '24 as under:-

Complaints pending at the beginning of the period	0
Complaints received during the period	0
Complaints disposed during the period	0
Complaints resolved at the end of the period	0

[8] List of the Entities Consolidated in the Statement:

Name of the Subsidiaries Companies	Relationship	% of Holding as on 30th June '24	Voting Power Either Directly or Indirectly through Subsidiaries
Sotac Healthcare Private Limited	Subsidiary	71.00	Directly
Sotac Research Private Limited	Subsidiary	100.00	Directly
Sotac Lifesciences Private Limited	Subsidiary	54.22	Directly



For & on behalf of Sotac Pharmaceuticals Limited

Sharad Patel

DIN:07252252

Chairman & Managing Director

Place : Ahmedabad

Date : 13th August, '24